Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

MLA

Brooks, Carl A., et al. “Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).” ACS Medicinal Chemistry Letters, vol. 10, no. 8, July 2019, pp. 1228–33. EBSCOhost, https://doi.org/10.1021/acsmedchemlett.9b00274.

APA

Brooks, C. A., Barton, L. S., Behm, D. J., Eidam, H. S., Fox, R. M., Hammond, M., Hoang, T. H., Holt, D. A., Hilfiker, M. A., Lawhorn, B. G., Patterson, J. R., Stoy, P., Roethke, T. J., Ye, G., Zhao, S., Thorneloe, K. S., Goodman, K. B., & Cheung, M. (2019). Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4). ACS Medicinal Chemistry Letters, 10(8), 1228–1233. https://doi.org/10.1021/acsmedchemlett.9b00274

Chicago

Brooks, Carl A, Linda S Barton, David J Behm, Hilary S Eidam, Ryan M Fox, Marlys Hammond, Tram H Hoang, et al. 2019. “Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).” ACS Medicinal Chemistry Letters 10 (8): 1228–33. doi:10.1021/acsmedchemlett.9b00274.